Thera-SAbDab

(Therapeutic Structural Antibody Database)

Search results

748 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page. Note that if the mAb name has been updated or a duplicate mAb name exists, your specific mAb search may return a different therapeutic name. See metadata notes for details.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)

TherapeuticFormatHighest Clinical Trial (Oct '21)Est. Status (Oct '21)TargetYear Proposed100% SI Struc.99% SI Struc.95-98% SI Struc.
abagovomabWhole mAbPhase-IIIDiscontinuedCA1252006nonono
abciximabFabApprovedNFDCD41_CD611993YESnono
abelacimabWhole mAbPhase-IIActiveF112018nonoYES
abituzumabWhole mAbPhase-IIActiveITGAV2013nonono
abrezekimabFabPhase-IDiscontinuedIL132017nonono
abrilumabWhole mAbPhase-IIDiscontinuedα4β72014nonono
acapatamabBispecific scFvPhase-I/IIActiveFOLH1;CD3E2020no;nono;nono;no
acasunlimabBispecific mAbPhase-I/IIActiveCD274;TNFRSF92020no;nono;nono;no
acrixolimabWhole mAbTBCActivePDCD12022nonono
actoxumabWhole mAbPhase-IIIDiscontinuedToxin A2012nonono
adalimumabWhole mAbApprovedActiveTNFA1999YESYESno
adebrelimabWhole mAbPhase-IIIActivePDL12019nonono
adintrevimabWhole mAbPhase-II/IIIActiveSARS-CoV-2 Spike2021nonono
aducanumabWhole mAbApprovedNFDAPP2013YESnono
afasevikumabWhole mAbPhase-IDiscontinuedIL17A2015YESnono
alacizumabdi-FabPhase-IIDiscontinuedKDR2007nonono
alemtuzumabWhole mAbApprovedActiveCD522000YESnono
alirocumabWhole mAbApprovedActivePCSK92012nonono
alnuctamabBispecific mAb with Domain CrossoverPhase-IActiveTNFRSF17;CD3E2020no;nono;nono;no
alomfilimabWhole mAbPhase-IIActiveICOS2020YESnono
alsevalimabWhole mAbPhase-IActiveVTCN12019nonono
amatuximabWhole mAbPhase-IIActiveMSLN2010noYESno
amivantamabBispecific mAbApprovedActiveEGFR;MET2019no;YESno;nono;no
amlitelimabWhole mAbPhase-IIActiveTNFSF42020nonono
amubarvimabWhole mAbPhase-II/IIIActiveSARS-CoV-2 Spike RBD2021YESYESno
anbenitamabBispecific mAbPhase-IIActiveERBB2 (Domain II);ERBB2 (Domain IV)2020no;YESno;YESno;YES
andecaliximabWhole mAbPhase-IIIDiscontinuedMMP92016YESnono
anetumabWhole mAb ADCPhase-IIActiveMSLN2013nonono
anifrolumabWhole mAbApprovedActiveIFNAR12013YESnono
anivovetmabCanine Whole mAbUnknownActiveVP2 (Canine)2022nonoYES
anrukinzumabWhole mAbPhase-IIDiscontinuedIL132007nonono
anselamimabWhole mAbPhase-IIActiveSAA12021nonono
ansuvimabWhole mAbApprovedActiveZaire Ebolavirus GP12020noYESno
anumigilimabWhole mAbPhase-IActiveCSF3R2021nonono
anzurstobartWhole mAbPhase-IActiveSIRPα2022nonono
apamistamabWhole mAb RadiolabelledPhase-IIIActivePTPRC2018nonono
apitegromabWhole mAbPhase-IIActivepro-GDF-82020nonoYES
aprutumabWhole mAb ADCPhase-IDiscontinuedFGFR22016nonono
ascrinvacumabWhole mAbPhase-IIActiveACVRL12015nonono
astegolimabWhole mAbPhase-IIActiveIL1RL12019nonono
atezolizumabWhole mAbApprovedActiveCD2742014YESYESno
atibuclimabWhole mAbPhase-IIActiveCD142020nonono
atidortoxumabWhole mAbPhase-IIDiscontinuedToxin A2017nonono
atinumabWhole mAbPhase-IDiscontinuedRTN42010nonono
atoltivimabWhole mAbPhase-IDiscontinuedZaire Ebolavirus GP2018nonono
avdoralimabWhole mAbPhase-IIActiveC5AR12019nonono
avelumabWhole mAbApprovedActiveCD2742015YESnono
avizakimabWhole mAbPhase-I/IIActiveIL212019nonono
axatilimabWhole mAbPhase-IIActiveCSF1R2019nonono
azintuxizumabWhole mAb ADCPhase-IDiscontinuedSLAMF72016nonono
bafisontamabBispecific Mixed mAb and FabPhase-I/IIActiveEGFR;MET2021YES;nono;nono;no
balstilimabWhole mAbPreregistrationActivePDCD12018nonono
bamlanivimabWhole mAbApprovedActiveSARS-CoV-2 Spike2020YESnono
bapineuzumabWhole mAbPhase-IIDiscontinuedAPP2005nonoYES
bapotulimabWhole mAbPhase-IActiveILDR22020nonono
barecetamabWhole mAbPhase-IActiveERBB32020YESnono
barzolvolimabWhole mAbPhase-IActiveKIT2021nonono
basiliximabWhole mAbApprovedNFDIL2RA1996YESnono
batoclimabWhole mAbPhase-IIIActiveFCGRT2019nonono
bavituximabWhole mAbPhase-IIIActivePhosphatidylserine2006nonono
bavunalimabBispecific Mixed mAb and scFvPhase-IActiveLAG3;CTLA42020no;nono;nono;no
bebtelovimabWhole mAbPhase-IIActiveSARS-CoV-2 Spike RBD2022YESnono
bedinvetmabCanine Whole mAbApprovedActiveCanine NGFB2018nonono
befovacimabWhole mAbPhase-IIActiveTFPI2019nonono
begelomabWhole mAbPhase-II/IIIActiveDPP42014nonono
belantamabWhole mAb ADCApprovedActiveTNFRSF172017nonono
belimumabWhole mAbApprovedActiveTNFSF13B2003YESnoYES
belrestotugWhole mAbPhase-IIActiveTIGIT2022nonono
beludavimabWhole mAbPhase-I/IIActiveSARS-CoV-2 Spike RBD2021noYESno
bemarituzumabWhole mAbPhase-IIIActiveFGFR22017nonoYES
benralizumabWhole mAbApprovedActiveIL5RA2009nonono
bentracimabWhole mAbPhase-IIIActiveAR-C124910XX2020YESnoYES
benufutamabWhole mAbPhase-I/IIActiveTNFRSF10B2019YESnono
bepranemabWhole mAbPhase-IIActiveMAPT2019nonono
berlimatoxumabWhole mAbPhase-IIDiscontinuedToxin A2017YESnono
bermekimabWhole mAbPreregistrationActiveIL1A2018nonono
bersanlimabWhole mAbPhase-IIDiscontinuedICAM12017nonono
betifisolimabWhole mAbTBCActiveCD2742022nonono
bevacizumabWhole mAbApprovedActiveVEGFA2000YESnoYES
bexmarilimabWhole mAbPhase-I/IIActiveSTAB12019nonono
bezlotoxumabWhole mAbApprovedNFDToxin A2012YESnono
bifikafuspWhole mAb FusionPhase-IIIActiveFN extra domain B2010nonono
bimagrumabWhole mAbPhase-IIActiveACVR2B2012YESYESno
bimekizumabWhole mAbApprovedActiveIL17A2013nonono
bintrafuspWhole mAb FusionApprovedActiveCD2742015YESnono
birtamimabWhole mAbPhase-IIIDiscontinuedSAA12018nonono
bleselumabWhole mAbPhase-IIDiscontinuedCD402015nonono
blinatumomabBispecific T-Cell EngagerApprovedActiveCD19;CD3E2008no;nono;nono;no
blontuvetmabCanine Whole mAbUnknownActiveMS4A12015nonono
blosozumabWhole mAbPhase-IIActiveSOST2011nonono
bococizumabWhole mAbPhase-IIIDiscontinuedPCSK92013YESnono
botensilimabWhole mAbPhase-IActiveCTLA42020nonono
brazikumabWhole mAbPhase-IIIActiveIL23A2016nonono
brentuximabWhole mAb ADCApprovedActiveTNFRSF82010nonono
briakinumabWhole mAbPreregistration (w)DiscontinuedIL12B2009YESnono
briquilimabWhole mAbTBCActiveKIT2022nonono
brodalumabWhole mAbApprovedActiveIL17RA2011nonono
brolucizumabscFvApprovedActiveVEGFA2014nonono
brontictuzumabWhole mAbPhase-IDiscontinuedNOTCH12014nonono
budigalimabWhole mAbPhase-IIActivePDCD12018nonono
burfiralimabWhole mAbTBCActiveVIM2022nonono
burosumabWhole mAbApprovedActiveFGF232016nonono
cabiralizumabWhole mAbPhase-IIActiveCSF1R2015nonono
cadonilimabBispecific Mixed mAb and scFvPhase-IIActivePDCD1;CTLA42020no;nono;nono;no
camidanlumabWhole mAb ADCPhase-IIActiveIL2RA2017nonono
camoteskimabWhole mAbTBCActiveIL182022nonono
camrelizumabWhole mAbApprovedActivePDCD12016nonono
canakinumabWhole mAbApprovedActiveIL1B2007noYESno
cantuzumabWhole mAb ADCPhase-IIDiscontinuedMUC12003nonono
caplacizumabNanobodyApprovedNFDVWF2011YESnono
carlumabWhole mAbPhase-IIDiscontinuedCCL22010noYESno
carotuximabWhole mAbPhase-IIDiscontinuedENG2015nonono
cemiplimabWhole mAbApprovedActivePDCD12018nonono
cendakimabWhole mAbPhase-IIIActiveIL132018nonono
cergutuzumabWhole mAb FusionPhase-IDiscontinuedCEACAM52015nonono
certolizumabFabApprovedActiveTNFA2004YESnono
cetrelimabWhole mAbPhase-IIIActivePDCD12017nonono
cetuximabWhole mAbApprovedActiveEGFR1999YESYESYES
cevostamabBispecific mAbPhase-IActiveFCRL5;CD32019no;nono;nono;no
cibisatamabBispecific mAb with Domain CrossoverPhase-I/IIActiveCEACAM5&CD3E;CD3E2017no;nono;nono;no
cifurtilimabWhole mAbTBCActiveCD402022nonono
cilgavimabWhole mAbPhase-IIIActiveSARS-CoV-2 Spike RBD2020YESnono
cinpanemabWhole mAbPhase-IIDiscontinuedSNCA2018YESnono
cirevetmabCanine Whole mAbUnknownActiveTGFB1 (Canine)2022nonono
citatuzumabFab FusionPhase-IDiscontinuedEPCAM2008nonono
cixutumumabWhole mAbPhase-IIDiscontinuedIGF1R2008nonono
clazakizumabWhole mAbPhase-IIIActiveIL62012nonono
clervonafuspdi-Fab FusionPhase-I/IIActiveSLC29A22018nonono
clesrovimabWhole mAbPhase-IIIActiveRSV gpF2022YESnono
clivatuzumabWhole mAb RadiolabelledPhase-IIIDiscontinuedMUC12009nonono
cobolimabWhole mAbPhase-II/IIIActiveHAVCR22018nonono
codrituzumabWhole mAbPhase-IIActiveGPC32013nonono
cofetuzumabWhole mAb ADCPhase-IActivePTK72017nonono
coltuximabWhole mAb ADCPhase-IIActiveCD192013YESnono
conatumumabWhole mAbPhase-IIActiveTNFRSF10B2008YESnono
concizumabWhole mAbPhase-IIIActiveTFPI2012YESnono
coprelotamabWhole mAbPhase-IIIActiveERBB22020YESYESYES
cosfroviximabWhole mAbPhase-IIActiveZaire Ebolavirus GP2016noYESno
cosibelimabWhole mAbPhase-I/IIActivePDL12019nonono
crefmirlimabscFv Engineered DimerPhase-IIActiveCD8A2022nonono
crenezumabWhole mAbPhase-IIIActiveAPP2011YESYESno
crexavibartWhole mAbTBCActiveSARS-CoV-2 Spike RBD2022YESnono
crizanlizumabWhole mAbApprovedActiveSELP2016nonono
crotedumabWhole mAbPhase-IDiscontinuedGCGR2015nonono
crovalimabWhole mAbPhase-IIIActiveC52018YESnono
cudarolimabWhole mAbPhase-IActiveTNFRSF42019nonono
cusatuzumabWhole mAbPhase-IIActiveCD702017nonono
dacetuzumabWhole mAbPhase-IIDiscontinuedCD402007nonono
daclizumabWhole mAbApprovedActiveIL2RA1994YESnono
dafsolimabWhole mAbPhase-IIIActiveCD3E2020nonono
dalotuzumabWhole mAbPhase-IIDiscontinuedIGF1R2009nonono
dalutrafuspWhole mAb FusionPhase-IActiveTGFBR22021nonono
danburstotugWhole mAb FusionPhase-IIActivePDL12022nonono
dapirolizumabFabPhase-IIIActiveCD40LG2013nonono
daratumumabWhole mAbApprovedActiveCD382009YESnono
datopotamabWhole mAbPhase-IIIActiveTACSTD22019nonono
daxdilimabWhole mAbPhase-IIActiveLILRA42020nonono
dectrekumabWhole mAbPhase-IIDiscontinuedIL132014nonono
demcizumabWhole mAbPhase-IDiscontinuedDLL42012nonono
demupitamabWhole mAbPhase-IActiveEGFR2019noYESno
denintuzumabWhole mAb ADCPhase-IIDiscontinuedCD192014nonono
denosumabWhole mAbApprovedActiveTNFSF112005nonono
depatuxizumabWhole mAb ADCPhase-IIIDiscontinuedEGFR2016nonono
depemokimabWhole mAbPhase-IIIActiveIL52020nonono
derlotuximabWhole mAb RadiolabelledApprovedActiveDNA/H1 Complex2015nonono
dezamizumabWhole mAbPhase-IIDiscontinuedAPCS2016nonono
dilpacimabBispecific mAbPhase-IIActiveDLL4;VEGFA2018no;YESno;nono;YES
dinutuximabWhole mAbApprovedActiveGanglioside GD22013nonoYES
diridavumabWhole mAbPhase-IIActiveInfluenza A HA22014YESnoYES
disitamabWhole mAb ADCApprovedActiveERBB22018nonono
divozilimabWhole mAbPhase-IIActiveMS4A12020nonono
docaravimabWhole mAb (Mouse)ApprovedActiveRabies Virus Strain ERA GP Ectodomain Epitope G-III2019nonono
domagrozumabWhole mAbPhase-IIDiscontinuedMSTN2015noYESno
domvanalimabWhole mAbPhase-IIIActiveTIGIT2020nonono
donanemabWhole mAbPhase-IIIActiveAPP2018nonono
dostarlimabWhole mAbApprovedActivePDCD12018nonono
dovanvetmabFeline Whole mAbUnknownActiveIL31 (Feline)2019nonono
dresbuxelimabWhole mAbPhase-IActiveNT5E2021nonono
drozitumabWhole mAbPhase-IIDiscontinuedTNFRSF10B2010YESnono
duligotuzumabWhole mAbPhase-IIDiscontinuedERBB32012nonoYES
dupilumabWhole mAbApprovedActiveIL4R2012YESnono
durvalumabWhole mAbApprovedActiveCD2742014YESnono
dusigitumabWhole mAbPhase-IIDiscontinuedIGF1&IGF22012nonono
duvortuxizumabBispecific scFv with CrossoverPhase-IDiscontinuedCD19;CD3E2016no;nono;nono;no
ebdarokimabWhole mAbPhase-I/IIActiveIL12B2020nonono
eblasakimabWhole mAbPhase-IActiveIL13RA12021nonoYES
ebronucimabWhole mAbPhase-IIActivePCSK92020nonono
ecleralimabWhole mAbPhase-IIActiveTSLP2021nonono
eculizumabWhole mAbApprovedActiveC52002YESnono
edrecolomabWhole mAbApproved (w)DiscontinuedEPCAM1995nonono
efalizumabWhole mAbApprovedNFDITGAL2001YESnono
efungumabscFvPhase-IIIDiscontinuedHeat Shock Protein 90 Homolog2006nonono
eldelumabWhole mAbPhase-IIDiscontinuedCXCL102013nonono
elezanumabWhole mAbPhase-IIActiveRGMA2016nonono
elgemtumabWhole mAbPhase-I/IIDiscontinuedERBB32014nonoYES
elipovimabWhole mAbPhase-IActiveHIV-1 gp1202018nonoYES
elotuzumabWhole mAbApprovedNFDSLAMF72008nonono
elranatamabBispecific Whole mAbPhase-IIActiveTNFRSF17;CD3E2021no;nono;nono;no
eluvixtamabBispecific scFvPhase-IActiveCD33;CD3E2020no;nono;nono;no
emactuzumabWhole mAbPhase-IIActiveCSF1R2014YESnono
emapalumabWhole mAbApprovedNFDIFNG2016nonono
emerfetamabBispecific scFvPhase-IActiveCD33;CD3E2020no;nono;nono;no
emibetuzumabWhole mAbPhase-IIActiveMET2014nonono
emicizumabBispecific mAbApprovedNFDF9;F102015no;nono;nono;no
emirodatamabBispecific scFv-scFv-scFcTBCActiveFLT3;CD3E2022no;nono;nono;no
enapotamabWhole mAb ADCPhase-IIDiscontinuedAXL2017nonono
enavatuzumabWhole mAbPhase-IDiscontinuedTNFRSF12A2010nonono
encelimabWhole mAbPhase-IActiveLAG32019nonono
enfortumabWhole mAb ADCApprovedNFDPVRL42013nonono
enibarcimabWhole mAbPhase-IIActiveADM2020nonono
enoblituzumabWhole mAbPhase-IIActiveCD2762015nonono
enokizumabWhole mAbPhase-IIDiscontinuedIL92010nonono
enoticumabWhole mAbPhase-IDiscontinuedDLL42012nonono
ensituximabWhole mAbPhase-IIActiveMUC5AC2010nonono
ensomafuspFusion ProteinPhase-IActiveCD192021nonono
enuzovimabWhole mAbPhase-IActiveSARS-CoV-2 Spike RBD2021YESnono
envafolimabSingle Domain Variable Fragment;HPreregistrationActivePDL12018nonono
epcoritamabBispecific mAbPhase-IIIActiveCD3E;MS4A12019no;nono;nono;YES
epratuzumabWhole mAbPhase-IIIDiscontinuedCD221999noYESno
eptinezumabWhole mAbApprovedActiveCALCA&CALCB2016nonono
eramkafuspWhole mAb FusionPhase-IActiveCD202020noYESno
erenumabWhole mAbApprovedNFDCALCRL2016YESnono
erfonrilimabBispecific Single Domains (VH-VH'-CH)Phase-IIActiveCD274;CTLA42020no;YESno;nono;no
etaracizumabWhole mAbPhase-IIDiscontinuedITGAV_ITGB32008nonono
etesevimabWhole mAbApprovedNFDSARS-CoV-2 Spike RBD2020YESnono
etevritamabBispecific scFvPhase-IDiscontinuedEGFR;CD3E2020no;nono;nono;no
etigilimabWhole mAbPhase-I/IIActiveTIGIT2017nonono
etokimabWhole mAbPhase-IIDiscontinuedIL132018nonono
etrolizumabWhole mAbPhase-IIIActiveITGA4_ITGB7&ITGAE_ITGB72010nonono
evinacumabWhole mAbApprovedActiveANGPTL32014nonono
evolocumabWhole mAbApprovedActivePCSK92012nonono
exidavnemabWhole mAbPhase-IActiveSNCA2021nonono
ezabenlimabWhole mAbPhase-IIActivePDCD12019nonono
faricimabBispecific mAbPreregistrationActiveVEGFA;ANGPT22017YES;nono;noYES;YES
farletuzumabWhole mAbPhase-IIIActiveFOLR12008nonono
fasinumabWhole mAbPhase-IIIActiveNGFB2012nonono
favezelimabWhole mAbPhase-IIActiveLAG32019nonono
fazpilodemabBispecific Whole mAbTBCActiveKLB;FGFR12022no;nono;nono;no
feladilimabWhole mAbPhase-IIIActiveICOS2019nonono
felzartamabWhole mAbPhase-IIIActiveCD382019nonono
fepixnebartWhole mAbPhase-IIActiveEREG2022YESnono
fezakinumabWhole mAbPhase-IDiscontinuedIL222009nonono
fianlimabWhole mAbPhase-IActiveLAG32019nonono
ficlatuzumabWhole mAbPhase-IIActiveHGF2011nonono
fidasimtamabBispecific Whole mAbPhase-IActivePDCD1;ERBB22021no;YESno;YESno;YES
figitumumabWhole mAbPhase-IDiscontinuedIGF1R2008nonono
finotonlimabWhole mAbPhase-IIIActivePDCD12020nonono
firivumabWhole mAbPreclinicalDiscontinuedInfluenza A HA2014nonono
fiztasovimabWhole mAbTBCActiveHHV gB AD-12022nonono
flanvotumabWhole mAbPhase-IDiscontinuedTYRP12011nonono
fletikumabWhole mAbPhase-IIDiscontinuedIL202013nonono
flotetuzumabBispecific scFv with CrossoverPhase-I/IIActiveIL3RA;CD3E2017no;nono;nono;no
fontolizumabWhole mAbPhase-IIDiscontinuedIFNG2002noYESno
foralumabWhole mAbPhase-IIActiveCD3E2010nonono
foravirumabWhole mAbPhase-IIDiscontinuedRV Antigenic Site III2008nonono
fremanezumabWhole mAbApprovedActiveCALCA&CALCB2016nonono
fresolimumabWhole mAbPhase-IDiscontinuedTGFB2009noYESno
frexalimabWhole mAbTBCActiveCD40LG2022nonono
frovocimabWhole mAbPhase-IIActivePCSK92018nonono
frunevetmabFeline Whole mAbUnknownActiveNGFB2016nonono
fulranumabWhole mAbPhase-IIIDiscontinuedNGFB2010noYESno
futuximabWhole mAbPhase-IIActiveEGFR2012nonono
galcanezumabWhole mAbApprovedNFDCALCA&CALCB2015nonono
galegenimabWhole mAbPhase-IIActiveHTRA12021nonono
galiximabWhole mAbPhase-IIDiscontinuedCD802003nonono
gancotamabscFvPhase-IIDiscontinuedERBB22018nonono
ganitumabWhole mAbPhase-IIIActiveIGF1R2010nonono
gantenerumabWhole mAbPhase-IIIActiveAPP2012YESnono
garadacimabWhole mAbPhase-IIIActiveF122018nonono
garetosmabWhole mAbPhase-IIActiveINHBA2018nonono
garivulimabWhole mAbPhase-I/IIActiveCD2742020nonono
gatipotuzumabWhole mAbPhase-IIActiveMUC12016nonono
gatralimabWhole mAbPhase-IDiscontinuedCD522019YESnono
gedivumabWhole mAbPhase-IIDiscontinuedInfluenza A HA2016nonoYES
gefurulimabBispecific Single Domains (VH-VH')Phase-IActiveC5;ALB2022no;nono;nono;no
gemtuzumabWhole mAb ADCApprovedNFDCD332016nonono
geptanolimabWhole mAbPreregistrationActivePDCD12020nonono
gevokizumabWhole mAbPhase-IIIActiveIL1B2010YESnono
giloralimabWhole mAbPhase-I/IIActiveCD402019nonono
gilvetmabCanine Whole mAbUnknownActivePDCD1 (Canine)2016nonono
gimsilumabWhole mAbPhase-IDiscontinuedCSF22017nonono
ginisortamabWhole mAbPhase-I/IIActiveGREM12021nonono
girentuximabWhole mAb RadiolabelledPhase-IIIDiscontinuedCA92009nonono
glembatumumabWhole mAb ADCPhase-IIIDiscontinuedGPNMB2015nonono
glenzocimabFabPhase-IIActiveGP62018nonono
glofitamabBispecific mAb with Domain CrossoverPhase-IIIActiveCD3E;MS4A12019no;YESno;YESno;YES
golimumabWhole mAbApprovedActiveTNFA2004YESnono
golocdacimabWhole mAbTBCActiveOLR12022nonono
gontivimabBispecific Single Domains (VH-VH'-VH')Phase-IIDiscontinuedRSV gpF;RSV gpF2019no;nono;nono;no
gosuranemabWhole mAbPhase-IIDiscontinuedMAPT2018nonono
gremubamabBispecific mAbPhase-IIDiscontinuedPcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas)2019no;nono;nono;no
gresonitamabBispecific scFv-scFv-scFcPhase-IActiveCLDN18;CD3E2021no;nono;nono;no
grisnilimabWhole mAbPhase-I/IIActiveCD72020nonono
gumokimabWhole mAbPhase-IActiveIL17A2021nonono
guselkumabWhole mAbApprovedActiveIL23A2013YESnono
ianalumabWhole mAbPhase-II/IIIActiveTNFRSF13C2017nonono
ibalizumabWhole mAbApprovedNFDCD42007YESnono
ibritumomabWhole mAbApprovedNFDMS4A11999YESnono
icrucumabWhole mAbPhase-IIDiscontinuedFLT12010nonono
idactamabWhole mAbPhase-IActiveSLC1A52020nonono
idarucizumabFabApprovedNFDDabigatran2013YESnono
ieramilimabWhole mAbPhase-IIActiveCD2232018nonono
ifabotuzumabWhole mAbPhase-IIActiveEPHA32015nonono
ifinatamabWhole mAbTBCActiveCD2762022nonono
iladatuzumabWhole mAb ADCPhase-IDiscontinuedCD79B2017nonono
imalumabWhole mAbPhase-IIDiscontinuedMIF2014YESnono
imaprelimabWhole mAbPhase-IDiscontinuedMCAM2017nonono
imgatuzumabWhole mAbPhase-IIDiscontinuedEGFR2012nonono
imsidolimabWhole mAbPhase-IIActiveIL36R2020nonono
imvotamabPentameric IgM with Fused scFvTBCActiveCD3E;MS4A12022no;nono;nono;no
inclacumabWhole mAbPhase-IIDiscontinuedSELP2011no;nono;nono;no
indatuximabWhole mAb ADCPhase-IIDiscontinuedSDC12011nonono
indusatumabWhole mAb ADCPhase-IIDiscontinuedGUCY2C2014nonono
inebilizumabWhole mAbApprovedActiveCD192015nonono
inezetamabBispecific Mixed mAb and scFvTBCActiveCD40;MSLN2022no;nono;nono;no
infliximabWhole mAbApprovedNFDTNFA1997YESnono
inotuzumabWhole mAb ADCApprovedActiveCD222004nonono
intetumumabWhole mAbPhase-IIDiscontinuedITGAV_ITGB32009nonono
iparomlimabWhole mAbPhase-IActivePDCD12021nonono
ipilimumabWhole mAbApprovedActiveCTLA42005YESnono
iratumumabWhole mAbPhase-IIDiscontinuedTNFRSF82005nonono
isatuximabWhole mAbApprovedActiveCD382014YESnono
iscalimabWhole mAbPhase-IIActiveCD402017nonono
isecarosmabBispecific Single Domains (VH-VH')Phase-IActiveADAMTSL5;ALB2019no;nono;nono;no
ispectamabWhole mAbTBCActiveTNFRSF172022nonono
istiratumabBispecific Mixed mAb and scFvPhase-IIDiscontinuedIGF1R;ERBB32017no;nono;nono;no
itepekimabWhole mAbPhase-IIIActiveIL332019nonono
itolizumabWhole mAbApprovedActiveCD62010nonono
ivicentamabBispecific Whole mAbPhase-I/IIActiveCD37;CD372021no;nono;nono;no
ivonescimabscFv-IGHCPhase-IIActiveVEGFA2021YESnoYES
ivuxolimabWhole mAbPhase-IIActiveTNFRSF42019nonono
ixekizumabWhole mAbApprovedActiveIL17A2011YESYESno
izalontamabBispecific Mixed mAb and scFvTBCActiveEGFR;ERBB32022YES;noYES;noYES;no
izenivetmabCanine Whole mAbUnknownActiveNGFB (Canine)2022nonono
izuralimabBispecific Mixed mAb and scFvPhase-IIActiveICOS;PDCD12020no;nono;nono;no
labetuzumabWhole mAb ADCPhase-IIDiscontinuedCEACAM52015nonono
lacnotuzumabWhole mAbPhase-IIActiveCSF12016nonono
lacutamabWhole mAbPhase-IIActiveKIR3DL22018nonono
ladiratuzumabWhole mAb ADCPhase-IIActiveSLC39A62017nonono
lanadelumabWhole mAbApprovedNFDKLKB12015YESnono
landogrozumabWhole mAbPhase-IIDiscontinuedMSTN2015nonono
laprituximabWhole mAb ADCPhase-IDiscontinuedEGFR2015nonono
larcaviximabWhole mAbPhase-IIActiveZaire Ebolavirus GP2016noYESno
latikafuspWhole mAb FusionTBCActivePDCD12022nonono
latozinemabWhole mAbPhase-IIIActiveSORT12020nonono
lebrikizumabWhole mAbPhase-IIIActiveIL132009YESnono
lecanemabWhole mAbPreregistrationActiveAPP2019nonono
lemzoparlimabWhole mAbPhase-IIActiveCD472020nonono
lenvervimabWhole mAbPhase-IIIActiveHBV2017nonono
lenzilumabWhole mAbPreregistrationActiveCSF22014nonono
lepunafuspWhole mAb FusionPhase-I/IIActiveTfR12021nonono
leronlimabWhole mAbPhase-IIIActiveCCR52017nonono
lesabelimabWhole mAbTBCActiveCD2742022nonono
lesofavumabWhole mAbPhase-IDiscontinuedInfluenza B Virus2016nonono
letaplimabWhole mAbPhase-I/IIActiveCD472020nonono
letolizumabSingle Domain Variable Fragment;HPhase-I/IIActiveCD40LG2016nonono
levilimabWhole mAbApprovedActiveIL6R2018nonono
lexatumumabWhole mAbPhase-IDiscontinuedTNFRSF10B2006nonoYES
licaminlimabscFvPhase-IIActiveTNFA2020nonono
lifastuzumabWhole mAb ADCPhase-IIDiscontinuedSLC34A22013nonono
ligelizumabWhole mAbPhase-IIIActiveIGHE2012YESnono
ligufalimabWhole mAbPhase-I/IIActiveCD472021nonono
lilotomabWhole mAb ADCPhase-IIActiveCD372014nonono
lintuzumabWhole mAb RadiolabelledPhase-IIDiscontinuedCD331996nonono
linvoseltamabBispecific Whole mAbPhase-IIActiveTNFRSF172022no;nono;nono;no
lirentelimabWhole mAbPhase-IIIActiveSIGLEC82020nonono
lirilumabWhole mAbPhase-IIActiveKIRD22012nonono
litifilimabWhole mAbPhase-IIIActiveCLEC4C2022nonono
livmoniplimabWhole mAbPhase-IActiveLRRC322021nonono
lodapolimabWhole mAbPhase-IActivePDL12019nonono
lodelcizumabWhole mAbPhase-IIDiscontinuedPCSK92012nonono
lokivetmabCanine Whole mAbApprovedNFDIL312014nonono
lomtegovimabWhole mAbPhase-I/IIActiveSARS-CoV-2 Spike RBD2021nonono
loncastuximabWhole mAb ADCApprovedActiveCD192017noYESno
lonigutamabWhole mAbPhase-I/IIActiveIGF1R2020nonono
lorigerlimabBispecific Mixed scFv (scFv-CH2-CH3-scFv)Phase-IActivePDCD1;CTLA42021no;nono;nono;YES
lorukafuspWhole mAb FusionPhase-IIActiveGanglioside GD22018nonoYES
lorvotuzumabWhole mAb ADCPhase-IIDiscontinuedNCAM12010nonono
losatuxizumabWhole mAb ADCPhase-IDiscontinuedEGFR2016nonono
lucatumumabWhole mAbPhase-IDiscontinuedCD402007nonono
lulizumabSingle Domain Variable Fragment;LPhase-IIActiveCD282014nonono
lumiliximabWhole mAbPhase-IIDiscontinuedFCER22004noYESno
lumretuzumabWhole mAbPhase-I/IIDiscontinuedERBB32014YESnono
lupartumabWhole mAb ADCPhase-IActiveLYPD32016nonono
lusvertikimabWhole mAbPhase-IActiveIL7R2020nonono
lutikizumabBispecific Dual Variable Domain IGPhase-IIDiscontinuedIL1A;IL1B2016no;nono;nono;no
luveltamabWhole mAb ADCTBCActiveFOLR12022nonono
maftivimabWhole mAbPreregistrationDiscontinuedZaire Ebolavirus GP2018nonono
magrolimabWhole mAbPhase-IIIActiveCD472018noYESno
manelimabWhole mAbPhase-IDiscontinuedPDL12019nonono
manfidokimabWhole mAbPhase-IActiveIL4R2021nonono
margetuximabWhole mAbApprovedActiveERBB22013nonono
marstacimabWhole mAbPhase-IIIActiveERBB22013nonono
masavibartWhole mAbApprovedActiveSARS-CoV-2 Spike RBD2020YESnono
matuzumabWhole mAbPhase-IIDiscontinuedEGFR2003YESYESno
mavrilimumabWhole mAbPhase-II/IIIActiveCSF2RA2009nonono
mazorelvimabWhole mAbPhase-I/IIActiveRabies Virus Spike Glycoprotein G2021nonono
mecbotamabWhole mAbPhase-IIActiveAXL2022nonono
melredableukinWhole mAb FusionPhase-IActiveNon-Binding2021noYESYES
melrilimabWhole mAbPhase-IIDiscontinuedIL1RL12020nonono
mepolizumabWhole mAbApprovedActiveIL51999nonono
mezagitamabWhole mAbPhase-IIActiveCD382019nonono
mibavademabWhole mAbPhase-IIActiveLEPR2020nonono
milatuzumabWhole mAbPhase-I/IIDiscontinuedCD742007nonono
mipasetamabWhole mAbPhase-IActiveAXL2020nonono
miptenalimabWhole mAbPhase-IIActiveLAG32019nonono
mirikizumabWhole mAbPhase-IIIActiveIL23A2017nonono
miromavimabWhole mAb (Mouse)ApprovedNFDRabies Virus Strain ERA GP Ectodomain Epitope G-II2019nonono
mirvetuximabWhole mAb ADCPhase-IIIActiveFOLR12015nonono
mirzotamabWhole mAbPhase-IDiscontinuedCD2762019nonono
mitazalimabWhole mAbPhase-I/IIActiveCD402017nonono
modakafuspWhole mAb FusionPhase-I/IIActiveADPRC2019nonono
modotuximabWhole mAbPhase-IIActiveEGFR2012nonono
mogamulizumabWhole mAbApprovedActiveCCR42010nonono
monalizumabWhole mAbPhase-IIIActiveKLRC12015nonono
mosunetuzumabBispecific mAbPhase-IIIActiveCD3E;MS4A12017no;nono;nono;YES
motavizumabWhole mAbPhase-IIIDiscontinuedRSV gpF2006YESYESno
moxetumomabFv FusionApprovedNFDCD222009nonono
mupadolimabWhole mAbPhase-IIIActiveNT5E2021nonono
murlentamabWhole mAbPhase-IIActiveAMHR22018nonono
muromonabWhole mAbApprovedDiscontinuedCD3E1988YESnono
nadecnemabWhole mAbPhase-IIActiveGFRA32020nonono
nadunolimabWhole mAbPhase-IIActiveIL1RAP2018nonono
namilumabWhole mAbPhase-IIActiveCSF22010nonono
naptumomabFab FusionPhase-IIIDiscontinuedTPBG2006nonono
naratuximabWhole mAb ADCPhase-IIActiveCD372015nonono
narnatumabWhole mAbPhase-IDiscontinuedMST1R2011nonono
narsoplimabWhole mAbPreregistrationActiveMASP22019nonono
natalizumabWhole mAbApprovedActiveITGA41998noYESno
navicixizumabBispecific mAbPhase-IActiveDLL4;VEGFA2015no;nono;nono;no
navivumabWhole mAbPreclinicalDiscontinuedInfluenza A HA2015YESYESno
naxitamabWhole mAbApprovedActiveGanglioside GD22018nonono
necitumumabWhole mAbApprovedActiveEGFR2008YESnono
nemolizumabWhole mAbPhase-IIIActiveIL31RA2014nonono
nepuvibartWhole mAbApprovedNFDSARS-CoV-2 Spike RBD2020YESnono
nesvacumabWhole mAbPhase-IDiscontinuedANGPT22012nonono
netakimabWhole mAbApprovedActiveIL17A2017nonono
nimacimabWhole mAbPhase-IIActiveCNR12018nonono
nimotuzumabWhole mAbApprovedActiveEGFR2005noYESno
nipocalimabWhole mAbPhase-IIIActiveFCGRT2019nonoYES
nirsevimabWhole mAbPhase-IIIActiveRSV2018YESnoYES
nivatrotamabBispecific Mixed mAb and scFvPhase-I/IIActiveGD2;CD3E2020no;nono;nono;no
nivolumabWhole mAbApprovedActivePDCD12012YESnono
nofazinlimabWhole mAbPhase-IIIActivePDCD12021nonono
nurulimabWhole mAbPhase-IDiscontinuedCTLA42019noYESno
obexelimabWhole mAbPhase-IIIActiveCD192018nonono
obiltoxaximabWhole mAbApprovedNFDAnthrax Protective Antigen2015nonono
obinutuzumabWhole mAbApprovedActiveMS4A12008YESYESYES
obrindatamabBispecific scFv with Domain CrossoverPhase-IDiscontinuedCD276;CD3E2020no;nono;nono;no
ocaratuzumabWhole mAbPhase-IIDiscontinuedMS4A12012nonono
ociperlimabWhole mAbPhase-IIIActiveTIGIT2020nonono
ocrelizumabWhole mAbApprovedNFDMS4A12005nonoYES
odesivimabWhole mAbApprovedActiveZaire Ebolavirus GP2019nonono
odronextamabBispecific mAbPhase-IIActiveMS4A1;CD3E2019no;nono;nono;no
ofatumumabWhole mAbApprovedActiveMS4A12005YESnono
ogalvibartWhole mAbTBCActiveSARS-CoV-2 Spike RBD2022YESnono
olaratumabWhole mAbApprovedActivePDGFRA2010nonono
oleclumabWhole mAbPhase-IIActiveNT5E2016nonono
olendalizumabWhole mAbPhase-IIActiveC52015nonono
olinvacimabWhole mAbPhase-IIActiveKDR2018nonono
olokizumabWhole mAbPhase-IIIActiveIL62010YESnoYES
omalizumabWhole mAbApprovedActiveIGHE2000YESYESYES
omburtamabWhole mAb RadiolabelledPhase-II/IIIActiveCD2762018YESnono
omodenbamabWhole mAbPhase-I/IIActiveSpA2020nonono
onartuzumabFab + di-FcPhase-IIIDiscontinuedMET2010YESnono
onfekafuspWhole mAb FusionPhase-IIIActiveFN extra domain B2010nonono
ongericimabWhole mAbPhase-IIIActivePCSK92019nonono
ontamalimabWhole mAbPhase-IIIDiscontinuedMADCAM12018YESnono
ontuxizumabWhole mAbPhase-IIActiveCD2482013nonono
onvatilimabWhole mAbPhase-IActiveVSIR2017nonono
opicinumabWhole mAbPhase-IIDiscontinuedLINGO12015YESnono
oportuzumabscFvPreregistrationActiveEPCAM2008nonono
opucolimabWhole mAbPhase-IDiscontinuedPDL12019nonono
ordesekimabWhole mAbPhase-I/IIActiveIL152020nonono
orilanolimabWhole mAbPhase-IIActiveFCGRT2018YESnono
ormutivimabWhole mAbPhase-IIActiveRabies Virus Surface Glycoprotein 4 (gp4) Epitope 12021nonono
orticumabWhole mAbPhase-IIActiveOxLDL2012nonono
osemitamabWhole mAbTBCActiveCLDN182022nonono
osocimabWhole mAbPhase-IIActiveF112018noYESno
otelixizumabWhole mAbPhase-IIActiveCD3E2007nonono
otilimabWhole mAbPhase-IIIActiveCSF22018noYESYES
otlertuzumabdi-scFv+FcPhase-IIDiscontinuedCD372013nonono
oxelumabWhole mAbPhase-IIDiscontinuedTNFSF42010nonono
ozanezumabWhole mAbPhase-IIDiscontinuedRTN42012nonono
ozoralizumabBispecific Single Domains (VH-VH'-VH)PreregistrationActiveTNFA;ALB2011no;nono;noYES;no
ozuriftamabWhole mAbPhase-IIActiveROR22022nonono
pabinafuspWhole mAb FusionApprovedActiveTFRC2018nonono
pacanalotamabBispecific scFvPhase-IActiveTNFRSF17;CD3E2020no;nono;nono;no
pacmilimabWhole mAbPhase-IIActivePDL12019nonono
palivizumabWhole mAbApprovedNFDRSV gpF1998noYESno
pamrevlumabWhole mAbPhase-IIIActiveCTGF2015nonono
panitumumabWhole mAbApprovedActiveEGFR2004YESnono
panobacumabWhole mAbPhase-IIActiveSerotype IATS O112008nonono
paridiprubartWhole mAbTBCActiveTLR42022YESnoYES
parsatuzumabWhole mAbPhase-IIDiscontinuedEGFL72012nonono
pasotuxizumabBispecific scFvPhase-IDiscontinuedFOLH1;CD3E2014no;nono;nono;no
pateclizumabWhole mAbPhase-IIDiscontinuedLTA2011YESnono
patritumabWhole mAbPhase-IIIActiveERBB32011nonono
pavurutamabBispecific scFvPhase-IActiveTNFRSF17;CD3E2020no;nono;nono;no
pelgifatamabWhole mAb ADCPhase-IActiveFOLH12020nonono
pembrolizumabWhole mAbApprovedActivePDCD12013YESnono
penpulimabWhole mAbApprovedActivePDCD12020nonono
pepinemabWhole mAbPhase-IIActiveSEMA4D2018nonono
perakizumabWhole mAbPhase-IDiscontinuedIL17A2012nonono
peresolimabWhole mAbPhase-IIActivePDCD12022nonono
pertuzumabWhole mAbApprovedActiveERBB22003YESnoYES
petosemtamabBispecific mAbPhase-IDiscontinuedEGFR;LGR52019no;nono;nono;no
pidilizumabWhole mAbPhase-IIActivePDCD12012nonono
pimivalimabWhole mAbPhase-IIActivePDCD12020nonono
pimurutamabWhole mAbPhase-I/IIActiveEGFR2019nonono
pinatuzumabWhole mAb ADCPhase-IIDiscontinuedCD222012noYESno
pivekimabWhole mAbPhase-I/IIActiveIL3RA2021nonono
placulumabSingle Domain Variable Fragment (VL) + FcPhase-IIDiscontinuedTNFA2012nonono
plamotamabBispecific Mixed mAb and scFvPhase-IActiveMS4A1;CD3E2018no;nono;nono;no
plonmarlimabWhole mAbPhase-II/IIIActiveCSF22020nonono
plozalizumabWhole mAbPhase-IIActiveCCR22015nonono
plutavimabWhole mAbTBCActiveSARS-CoV-2 Spike RBD2022nonono
polatuzumabWhole mAb ADCApprovedActiveCD79B2012nonono
ponezumabWhole mAbPhase-IIDiscontinuedAPP2010YESnono
ponsegromabWhole mAbPhase-IDiscontinuedGDF152020nonono
porgaviximabWhole mAbPhase-IIDiscontinuedZaire Ebolavirus GP2016noYESno
posdinemabWhole mAbTBCActiveMAPT2022nonono
praluzatamabWhole mAbPhase-IIActiveCD1662019nonono
prasinezumabWhole mAbPhase-IIActiveSNCA2017nonono
prezalumabWhole mAbPhase-IIDiscontinuedICOSLG2015YESnono
pritoxaximabWhole mAbPhase-IIDiscontinuedShiga Toxin Type 12012nonono
prolgolimabWhole mAbPhase-IIIActivePDCD12018nonono
pucotenlimabWhole mAbPhase-IIActivePDCD12020nonono
pulocimabWhole mAbPhase-I/IIActiveVEGFR22021noYESno
quavonlimabWhole mAbPhase-IIActiveCTLA42019nonono
quetmolimabWhole mAbPhase-IIActiveCX3CL12018nonono
quilizumabWhole mAbPhase-IIDiscontinuedIGHE2011YESnono
quisovalimabWhole mAbPhase-IIActiveTNFSF142021nonono
racotumomabWhole mAbApprovedActiveIdiotope of anti-NeuGc-ganliosides2008nonono
radretumabdi-scFv + CH4Phase-IIDiscontinuedFN extra domain B2010nonono
rafivirumabWhole mAbPhase-IIDiscontinuedRV Antigenic Site III2008nonono
ragifilimabWhole mAbPhase-IIActiveTNFRSF182019nonono
ralpancizumabWhole mAbPhase-IDiscontinuedPCSK92013nonoYES
ramucirumabWhole mAbApprovedActiveKDR2008YESnono
ranevetmabCanine Whole mAbUnknownActiveNGFB2016nonono
ranibizumabFabApprovedActiveVEGFA2004YESnoYES
ravagalimabWhole mAbPhase-IIActiveCD402017YESnoYES
ravulizumabWhole mAbApprovedActiveC52017noYESno
recaticimabWhole mAbPhase-IActivePCSK92020nonono
refanezumabWhole mAbPhase-IIDiscontinuedMAG2015nonono
regdanvimabWhole mAbApprovedActiveSARS-CoV-2 Spike RBD2020YESnono
relatlimabWhole mAbPhase-II/IIIActiveLAG32018nonono
relfovetmabFeline Whole mAbUnknownActiveNGFB2018nonono
remtolumabBispecific Dual Variable Domain IGPhase-IIDiscontinuedIL17A;TNFA2016YES;noYES;nono;no
reozalimabBispecific Whole mAbTBCActivePDCD1;CD2742022no;nono;nono;no
reslizumabWhole mAbApprovedActiveIL52001nonono
retifanlimabWhole mAbPreregistrationActivePDCD12019nonono
retlirafuspWhole mAb FusionPhase-I/IIActiveCD2742020nonono
revdofilimabWhole mAbPhase-IIActiveTNFRSF42019nonono
rilotumumabWhole mAbPhase-IIDiscontinuedHGF2009nonono
rimteravimabMixed Nanobody (VHH-CH2-CH3 dimer)Phase-I/IIActiveSARS-CoV-2 Spike RBD2021nonono
rinucumabWhole mAbPhase-IIDiscontinuedPDGFRB2015nonono
ripertamabWhole mAbPhase-IIIActiveMS4A12019YESYESno
risankizumabWhole mAbApprovedActiveIL23A2015nonono
rituximabWhole mAbApprovedActiveMS4A11997YESYESno
rivabazumabFabPhase-IIDiscontinuedPcrV type III secretion system2015nonono
robatumumabWhole mAbPhase-IIDiscontinuedIGF1R2008nonono
rocatinlimabWhole mAbPhase-IIActiveTNFRSF42021nonono
roledumabWhole mAbPhase-II/IIIActiveRHD2010nonono
rolinsatamabWhole mAb ADCPhase-IActivePRLR2018nonono
romilkimabBispecific Dual Variable Domain IGPhase-IIDiscontinuedIL13;IL42017no;nono;nono;no
romlusevimabWhole mAbPhase-II/IIIActiveSARS-CoV-2 Spike RBD2021nonono
romosozumabWhole mAbApprovedNFDSOST2011nonono
rontalizumabWhole mAbPhase-IIDiscontinuedIFNA12009YESnono
rosmantuzumabWhole mAbPhase-IDiscontinuedRSPO32016nonono
rosnilimabWhole mAbPhase-IIActivePDCD12022nonono
rosopatamabWhole mAbPhase-IIIActiveFOLH12019nonono
rovalpituzumabWhole mAb ADCPhase-IIIDiscontinuedDLL32015nonono
rozanolixizumabWhole mAbPhase-IIIActiveFCGRT2016YESnono
rozibafuspWhole mAb FusionPhase-IIActiveICOS2018YESnono
rulonilimabWhole mAbPhase-IActivePDCD12021nonono
runimotamabBispecific mAbPhase-IActiveERBB2;CD3E2020YES;noYES;noYES;no
ruplizumabWhole mAbPhase-IIDiscontinuedCD40LG2000YESnono
sabatolimabWhole mAbPhase-IIIActiveHAVCR22019nonono
sacituzumabWhole mAb ADCApprovedActiveTACSTD22016nonono
samalizumabWhole mAbPhase-IDiscontinuedCD2002010nonono
samrotamabWhole mAb ADCPhase-IIIActiveLRRC152017nonono
sarilumabWhole mAbApprovedActiveIL6R2011nonono
sasanlimabWhole mAbPhase-IIIActivePDCD12019YESnono
satralizumabWhole mAbApprovedNFDIL6R2015nonono
secukinumabWhole mAbApprovedActiveIL17A2009YESnono
selicrelumabWhole mAbPhase-IDiscontinuedCD402016nonono
semorinemabWhole mAbPhase-IIActiveMAPT2018nonono
semzuvolimabWhole mAbTBCActiveCD42022nonono
serclutamabWhole mAb ADCPhase-IDiscontinuedEGFR2016nonono
seribantumabWhole mAbPhase-IIDiscontinuedERBB32012nonono
serplulimabWhole mAbPreregistrationActivePDCD12019YESnono
setoxaximabWhole mAbPhase-IIDiscontinuedShiga Toxin Type 22012nonono
setrusumabWhole mAbPhase-IIActiveSOST2017nonono
sibeprenlimabWhole mAbPhase-IActiveTNFSF132020nonono
sifalimumabWhole mAbPhase-IIDiscontinuedIFNA12009YESnono
siltuximabWhole mAbApprovedActiveIL62008nonono
simlukafuspWhole mAb FusionPhase-IIActiveFAP2019nonono
simridarlimabBispecific Mixed mAb/VH-VH-CH2-CH3Phase-IIActiveCD47;CD2742021no;nono;nono;no
simtuzumabWhole mAbPhase-IIDiscontinuedLOXL22012nonono
sintilimabWhole mAbApprovedActivePDCD12018nonono
sirexatamabWhole mAbPhase-IIActiveDKK12021nonono
sirtratumabWhole mAb ADCPhase-IActiveSLITRK62017nonono
sirukumabWhole mAbPhase-IIIActiveIL62011nonono
socazolimabWhole mAbPhase-IIIActiveCD2742021nonono
sofituzumabWhole mAb ADCPhase-IDiscontinuedMUC162013nonono
solanezumabWhole mAbPhase-IIIActiveAPP2008noYESno
solitomabBispecific scFvPhase-IDiscontinuedEPCAM;CD3E2011no;nono;nono;no
sotevtamabWhole mAbPhase-IActiveCLU2021nonono
sotigalimabWhole mAbPhase-IIActiveCD402020nonono
sotrovimabWhole mAbApprovedActiveSARS-CoV-2 Spike RBD2020noYESYES
spartalizumabWhole mAbPhase-IIActivePDCD12017nonono
spesolimabWhole mAbPhase-IIIActiveIL36RN2018YESnono
suciraslimabWhole mAbTBCActiveCD222021nonono
sudubrilimabWhole mAbUnknownActiveCD2742020nonoYES
sugemalimabWhole mAbPreregistrationActivePDL12019nonono
suptavumabWhole mAbPhase-IIIDiscontinuedRSV gpF2016nonono
surzebiclimabWhole mAbPhase-I/IIActiveHAVCR22020nonono
sutimlimabWhole mAbPreregistrationActiveC1S2017nonono
suvizumabWhole mAbPhase-IDiscontinuedHIV-1 gp1202009YESnono
suvratoxumabWhole mAbPhase-IIActiveToxin A2016YESnono
tabalumabWhole mAbPhase-IIIDiscontinuedTNFSF13B2011nonono
tabituximabWhole mAb ADCPhase-IDiscontinuedFZD102018nonono
tadocizumabFabPhase-IIDiscontinuedITGA2B_ITGB32005nonono
tafasitamabWhole mAbApprovedActiveCD192018nonono
tafolecimabWhole mAbPhase-IIIActivePCSK92019nonono
tagitanlimabWhole mAbPhase-IIActiveCD2742021nonono
talacotuzumabWhole mAbPhase-IIIActiveIL3RA2017YESnono
talquetamabBispecific mAbPhase-IIActiveGPRC5D;CD3E2019no;nono;nono;no
tamgiblimabWhole mAbPhase-IActiveTIGIT2021nonono
tamrintamabWhole mAb ADCPhase-IActiveDPEP32018YESnono
tamtuvetmabCanine Whole mAbUnknownActiveCD522015nonoYES
tanezumabWhole mAbPreregistrationActiveNGFB2008YESnono
tarcocimabWhole mAbTBCActiveVEGFA2021YESnoYES
tarextumabWhole mAbPhase-IIActiveNOTCH2&32013nonono
tarlatamabBispecific scFvPhase-IActiveDLL3;CD3E2020no;nono;nono;no
tavolimabWhole mAbPhase-IIDiscontinuedTNFSF42016nonono
tebentafuspscFv FusionPreregistrationActiveCD3E2017nonono
tebotelimabBispecific scFv with CrossoverPhase-II/IIIActivePDCD1;LAG32019no;nono;nono;no
tecaginlimabBispecific Whole mAbPhase-I/IIActiveCD40;TNFRSF92021no;nono;nono;no
teclistamabBispecific mAbPhase-IIActiveTNFRSF17;CD3E2018no;nono;nono;no
telazorlimabWhole mAbPhase-IIActiveTNFRSF42019nonono
telisotuzumabWhole mAb ADCPhase-IDiscontinuedMET2016nonono
temelimabWhole mAbPhase-IIActiveMRSV envelope protein2018nonono
tenatumomabWhole mAb RadiolabelledPhase-IDiscontinuedTNC2007nonono
teplizumabWhole mAbPreregistrationActiveCD3E2007nonono
tepoditamabBispecific mAbPhase-IDiscontinuedCLEC12A;CD3E2017no;nono;nono;no
teprotumumabWhole mAbApprovedActiveIGF1R2009nonono
teropavimabWhole mAbPhase-IIActiveHIV-1 gp120 CD4bs2021noYESno
tesidolumabWhole mAbPhase-IIActiveC52014nonono
tesnatilimabWhole mAbPhase-IIActiveKLRK12019nonono
tezepelumabWhole mAbPreregistrationActiveTSLP2015YESnono
tibulizumabBispecific Mixed mAb and scFvPhase-IDiscontinuedTNFSF13B;IL17A2017no;nono;nono;YES
tidutamabBispecific Mixed mAb and scFvPhase-IDiscontinuedSSTR2;CD3E2018no;nono;nono;no
tifcemalimabWhole mAbPhase-I/IIActiveBTLA2019nonono
tigatuzumabWhole mAbPhase-IIDiscontinuedTNFRSF10B2007nonono
tilavonemabWhole mAbPhase-IIActiveMAPT2018nonono
tildrakizumabWhole mAbApprovedActiveIL23A2012nonono
tilogotamabWhole mAbPhase-I/IIActiveTNFRSF10B2019noYESno
tilvestamabWhole mAbPhase-IActiveAXL2019nonono
timigutuzumabWhole mAbPhase-INFDERBB21997YESYESYES
timolumabWhole mAbPhase-IIDiscontinuedAOC32015nonono
tinurilimabWhole mAbPhase-IDiscontinuedCEACAM62019nonono
tiragolumabWhole mAbPhase-IIIActiveTIGIT2017nonono
tirnovetmabWhole mAb (Canine)UnknownActiveIL31 (Canine)2020nonono
tislelizumabWhole mAbApprovedActivePDCD12017YESnono
tisotumabWhole mAbPreregistrationActiveF32015nonono
tixagevimabWhole mAbPhase-IIIActiveSARS-CoV-2 Spike RBD2020YESYESYES
tocilizumabWhole mAbApprovedActiveIL6R2004nonono
tomaralimabWhole mAbPhase-IIActiveTLR22018nonono
tomuzotuximabWhole mAbPhase-IIActiveEGFR2016noYESYES
toripalimabWhole mAbApprovedActivePDCD12018YESnono
torudokimabWhole mAbPhase-IIActiveIL332020nonono
tosatoxumabWhole mAbPhase-IIIActiveToxin A2013nonono
tovetumabWhole mAbPhase-IIDiscontinuedPDGFRA2013nonono
tozorakimabWhole mAbPhase-IIActiveIL332020nonono
tralokinumabWhole mAbApprovedActiveIL132009YESnono
trastuzumabWhole mAbApprovedNFDERBB21997YESYESYES
tregalizumabWhole mAbPhase-IIDiscontinuedCD42010nonono
tremelimumabWhole mAbPhase-IIIActiveCTLA42005YESnono
trevogrumabWhole mAbPhase-IIActiveMSTN2015nonono
trinbelimabWhole mAbTBCActiveRhD2021nonono
trontinemabBispecific Mixed Format with Domain CrossoverTBCActiveAPP Abeta 1-40/42;TFRC2022YES;nono;nono;no
tusamitamabWhole mAbPhase-IIIActiveCEACAM52020nonono
tuvonralimabWhole mAbPhase-IActiveCTLA42021nonono
ubamatamabBispecific Whole mAbPhase-I/IIActiveMUC16;CD3E2021no;nono;nono;no
ublituximabWhole mAbPreregistrationActiveMS4A12010nonono
ulenistamabWhole mAbPreclinicalActivePAUF2021nonono
uliledlimabWhole mAbPhase-I/IIActiveNT5E2020nonono
ulocuplumabWhole mAbPhase-I/IIActiveCXCR42013nonono
unasnemabWhole mAbPhase-IActiveRGMA2020nonono
upanovimabWhole mAbPhase-I/IIActiveSARS-CoV-2 Spike RBD2021nonoYES
upifitamabWhole mAbPhase-I/IIActiveSLC34A22019nonono
urabrelimabWhole mAbPhase-IDiscontinuedCD472019nonono
urelumabWhole mAbPhase-IIActiveTNFRSF92010YESnono
ustekinumabWhole mAbApprovedActiveIL12B2008YESnono
utomilumabWhole mAbPhase-IIActiveTNFRSF92016YESnono
vadastuximabWhole mAb ADCPhase-IIIDiscontinuedCD332015nonono
valanafuspWhole mAb FusionPhase-IIActiveINSR2017noYESYES
vandortuzumabWhole mAb ADCPhase-IDiscontinuedSTEAP12014nonono
vantictumabWhole mAbPhase-IDiscontinuedFZD Family2013nonono
vanucizumabBispecific mAbPhase-IIDiscontinuedANGPT2;VEGFA2014YES;YESno;nono;YES
varisacumabWhole mAbPhase-II/IIIActiveVEGFA2016nonono
varlilumabWhole mAbPhase-IIActiveCD272014nonono
vatelizumabWhole mAbPhase-II/IIIDiscontinuedITGA22011nonono
vedolizumabWhole mAbApprovedActiveITGA4_ITGB72008nonono
veltuzumabWhole mAbPhase-IIDiscontinuedMS4A12007nonono
vepsitamabBispecific scFv-scFv-scFcPhase-IActiveMUC17;CD3E2021no;nono;nono;no
vesencumabWhole mAbPhase-IDiscontinuedNRP12010YESnono
vibecotamabBispecific Mixed mAb and scFvPhase-IActiveIL3RA;CD3E2018no;nono;nono;no
vibostolimabWhole mAbPhase-IIIActiveTIGIT2019nonono
vilamakitugWhole mAbTBCActiveIL1A2022nonono
vilobelimabWhole mAbPhase-IIIActiveC52019nonono
visilizumabWhole mAbPhase-IIIDiscontinuedCD3E2000nonono
visugromabWhole mAbTBCActiveGDF152022nonono
vixarelimabWhole mAbPhase-IIActiveOSMR2020nonono
vixtimotamabBispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)Phase-IActiveCD3E;CD332020no;nono;nono;no
vobarilizumabBispecific Single Domains (VH-VH')Phase-IIDiscontinuedIL6R;ALB2015no;nono;nono;no
vobramitamabWhole mAbTBCActiveCD2762022nonono
vofatamabWhole mAbPhase-I/IIActiveFGFR32018nonoYES
volagidemabWhole mAbPhase-IIActiveGCCR2018noYESno
volrustomigBispecific mAbTBCActiveCTLA4;PDCD12022YES;nono;nono;no
vonlerolizumabWhole mAbPhase-IIDiscontinuedTNFRSF42015YESnono
vopratelimabWhole mAbPhase-IIActiveICOS2017nonono
vorsetuzumabWhole mAb ADCPhase-IIDiscontinuedCD702012nonono
voxalatamabBispecific Whole mAbPhase-IActiveFOLH1;CD3E2021no;nono;nono;no
vudalimabBispecific Mixed mAb and scFvPhase-IIActiveCTLA4;PDCD12020no;nono;noYES;no
vulinacimabWhole mAbPhase-IActiveVEGFR22019nonono
vunakizumabWhole mAbPhase-IIActiveIL17A2016nonono
xeligekimabWhole mAbPhase-IActiveIL17A2021nonono
xentuzumabWhole mAbPhase-IIActiveIGF1&IGF22015nonono
zagotenemabWhole mAbPhase-IIActiveMAPT2019nonono
zalifrelimabWhole mAbPhase-IIActiveCTLA42018nonono
zalutumumabWhole mAbPhase-IIDiscontinuedEGFR2005nonono
zamerovimabWhole mAbPhase-I/IIActiveRabies Virus Spike Glycoprotein G2021nonono
zampilimabWhole mAbPhase-I/IIActiveTGM22018nonono
zanidatamabBispecific mAbPhase-IIIActiveERBB2;ERBB22019no;YESno;YESYES;YES
zanolimumabWhole mAbPhase-IIIDiscontinuedCD42004nonono
zansecimabWhole mAbPhase-IIActiveANGPT22020nonono
zelminemabWhole mAbPhase-IIActiveADCYAP1R12019nonono
zeluvalimabWhole mAbPhase-IActivePDCD12020nonono
zenocutuzumabBispecific mAbPhase-IIActiveERBB3;ERBB22017YES;YESno;nono;no
zilovertamabWhole mAbPhase-I/IIActiveROR12020nonono
ziltivekimabWhole mAbPhase-IIIActiveIL62019nonono
zimberelimabWhole mAbApprovedActivePDCD12020nonono
zinlirvimabWhole mAbTBCActiveHIV-1 gp120 V32022YESYESYES
zolbetuximabWhole mAbPhase-IIIActiveCLDN182017nonono
zuberitamabWhole mAbPhase-IIDiscontinuedMS4A12019nonoYES

Search again

>   About
  • This database is described in the following paper: Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):gkz827.
  • Antibody- and Nanobody-derived therapeutics with known sequences, and their structural coverage in the PDB.
  • Use the 'Get all therapeutics' tab to get a list of all immunotherapeutics.
  • Search by name: Find a specific entry using its INN -mab or -fusp name.
  • Search by attribute: Find a subset of immunotherapeutics with particular attributes. Choose from format, target, highest clinical trial reached, development status, year INN proposed, or structural coverage (or any combination).
  • Search by sequence: Find therapeutics near to your query sequence over any Chothia-defined region of the heavy and/or light chain variable domain sequence.
  • For more help, see the About page.
  • If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk
  • Please note that the data contained within Thera-SAbDab is available under a CC-BY 4.0 license.
  • On 19th October 2021, we updated Thera-SAbDab to filter out duplicate mAb names (i.e. where two names exist for the same mAb therapeutic) from the search results. Entries now bear the most recent mAb name. The former name is available in the metadata notes, and specific searches for the old mAb name will still return a datapoint labelled with the new name. Note that this does not mean Thera-SAbDab is completely sequence non-redundant; for example some bispecifics use identical Fv regions to previous monoclonal antibodies, while biosimilars can be identical in Fv sequence to their 'parent' mAb. Many thanks to Max Vasquez (Adimab) for suggesting this improvement.
  • On 1st February 2022, we updated Thera-SAbDab with the latest WHO Proposed List (PL126). One therapeutic (emfizatamab) is tetraspecific and so requires a change to the backend code of Thera-SAbDab. It is therefore temporarily not listed in the database while we find time to make this code change. This message will disappear once this therapeutic has been added.
>   Search for a specific therapeutic
Please type a therapeutic INN name:
>   Search therapeutics by attribute
Therapeutic format:
Year INN Proposed:
Highest Clinical Trial:
Developmental Status:
Target:
Restrict to Known Structures:
>   Search for therapeutics by sequence similarity
Heavy chain sequence:
Light chain sequence:
Max No. of Therapeutics to be returned:
Minimum sequence identity:
Region to consider:
>   Downloads

Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.

Download a spreadsheet of all therapeutic sequences/structures (last list(s) - PL126): xlsx / csv

If you find we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy